Skip to search formSkip to main contentSkip to account menu

parnaparin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and safety in prevention of venous… 
Review
2008
Review
2008
SummaryAbstractParnaparin (Fluxum™) is a low molecular weight heparin (LMWH) that is effective and generally well tolerated in… 
2007
2007
BackgroundThere are limited data on appropriate dosing of low-molecular-weight heparins (LMWHs) for venous thromboembolism (VTE… 
Highly Cited
2006
Highly Cited
2006
The currently available brand-name low-molecular-weight heparins (LMWHs) in the United States include dalteparin (Pfizer… 
2005
2005
Long-term administration of heparin can lead to development of osteoporosis. The aim of the present study was to examine the… 
Review
2004
Review
2004
It is now widely accepted that various low-molecular-weight heparins (LMWHs) exhibit specific molecular and structural attributes… 
2004
2004
AIM Thrombin activatable fibrinolytic inhibitor (TAFI) is activated via cleavage by thrombin thrombomodulin in complex, and can… 
2002
2002
Background: There is increasing evidence for the role of nitric oxide (NO) in haemodialysis hypotension but the source of… 
Review
1994
Review
1994
Parnaparin is a low molecular weight (LMW) heparin which, like other members of its class, apparently demonstrates a greater…